Wobble Genomics Ltd

Excited to unveil another exciting application of Wobble Genomics Ltd’s platform, building on our results from October that demonstrated the strong predictive diagnostic potential of our technology in early-stage breast cancer. Today at the San Antonio Breast Cancer Symposium (SABCS), we’re presenting our latest findings on how our long-read RNA sequencing platform could advance oncology drug discovery and development.   From our prospective breast cancer study, we’ve identified hundreds of thousands of novel full-length RNA isoforms, including cancer-specific variants of oncogenes and tumour suppressors. These discoveries hold immense potential for drug development, paving the way for highly targeted treatments such as RNA-based cancer vaccines and antibody-drug conjugates (ADCs).   We’ve captured these novel RNA isoforms in our comprehensive database, which now includes over 35,000 cancer-specific RNA isoforms. These targets reflect shared tumour-specific properties across the patients from our studies, creating an exciting opportunity to develop scalable, yet precise, cancer therapies.   Our platform also provides a comprehensive view of the immune system, unlocking important insights into immune dynamics. This could enable the development of immunotherapies tailored to individual immune profiles, further advancing precision oncology with treatments designed to optimise outcomes, while minimising harm to healthy tissues.   Read our full press release for more details: https://bit.ly/49BKP8s   If you’re attending SABCS, don’t miss the chance to discuss these exciting developments with our Founder and CEO, Dr. Richard Kuo, and Chief Medical Officer, Dr. Richard Hockett and myself at the poster session today at 12:30 – 14:00 CST.   A big thank you to the brilliant team at Wobble Genomics Ltd for all their hard work.   We have a lot more exciting news to come!   #SABCS24 #RNASequencing #DrugDiscovery #OncologyInnovation #WobbleGenomics

🎉 Today we are proud to be presenting our latest advancements at the San Antonio Breast Cancer Symposium (SABCS) in Texas!   Our new data reveals:   - Our technology’s promise as a tool for the discovery of new – broadly applicable, yet highly specific – therapeutic targets, including mRNA cancer vaccines and antibody-drug conjugates (ADCs) - Our platform’s ability to provide a comprehensive view of the patient’s immune system – enabling patient stratification and the potential development of immunotherapies tailored to specific immune profiles.   This builds on previous data that established our technology’s strong predictive performance as a diagnostic tool and demonstrates the significant potential of our technology across a range of applications – from diagnostics and treatment monitoring, to target discovery and drug development.   Read more about our data here: https://bit.ly/49BKP8s   📍 If you’re attending SABCS, make sure to visit our poster presentation taking place at 12:30pm to learn more!   #SABCS24 #RNASequencing

💡 We’re excited to announce that our work has been spotlighted in GenomeWeb! A huge thank you to Huanjia Zhang for the insightful conversation with Wobble Genomics’ Founder and CEO, Richard Kuo, about our novel technology. Read in full here: https://bit.ly/3CM4HcO   At Wobble Genomics, we’re using innovative solutions that use full-length RNA transcripts as biomarkers, with potential applications across multiple oncology indications and disease areas. As Richard shared during the interview, we are excited to further develop our technology and “want to work with people who are experts in different fields” to enable collaboration.      By detecting RNA that was previously invisible, we can see more, understand more, and ultimately do more.   #WobbleGenomics #LongReadSequencing #InnovationInDiagnostics

🎥 Investment Manager, Lee Lindley explains a little more about why Mercia Ventures led a £8.5million fundraise into Wobble Genomics Ltd, and details how its groundbreaking technology could be transformational in helping to change people's outcomes. Full video ➡️ https://hubs.li/Q02ZFYkQ0 #VCT #WhyWeInvested #Genomics #RNA #Investment #VentureCapital

🎥 Investment Manager, Lee Lindley explains a little more about why Mercia Ventures led a £8.5million fundraise into Wobble Genomics Ltd, and details how its groundbreaking technology could be transformational in helping to change people's outcomes. Full video link in comments ⏬ #VCT #WhyWeInvested #Genomics #RNA #Investment #VentureCapital

Wobble Genomics Ltd has emerged from stealth mode, revealing revolutionary early detection technology for breast cancer.🧬 At a recent conference in San Francisco, Wobble Genomics showcased their cutting-edge technology that detects rare RNA transcript variants missed by other methods. In March, we proudly led a £8.5 million funding round in Edinburgh-based Wobble Genomics as part of our early-stage offering. To find out more about Wobble's technology, read the full press release here: https://lnkd.in/eyfTRmjs #CancerDetection #LifeSciences #Genomics #Investment #Technology

🔬 In March of this year, Mercia Ventures led a £8.5million fundraise into Edinburgh-based Wobble Genomics Ltd. Wobble has found a way to detect previously invisible ‘full length’ RNA, and the technology could have wide-ranging applications, from drug development and research to agriculture and ecology. CEO and Founder Dr Richard Kuo explains more about this technology that will have a massive impact on the future of health care, biosecurity and biodiversity. Full video link in comments ⏬ #VCT #Edinburgh #Genomics #RNA #BioTech #Investment #VentureCapital

Excited to unveil the groundbreaking work Wobble Genomics Ltd is doing now that we've emerged from stealth mode: we are now able to see cancer in a way that has never been seen before. Today at the Early Detection of Cancer Conference (EDCC) in San Francisco, we're presenting our innovative diagnostics platform using long read RNA sequencing. From our prospective breast cancer clinical study, we've demonstrated ability to detect rare full-length RNA transcript variants not picked up by other methods. By leveraging these full-length transcripts as biomarkers, we achieved 80% sensitivity and 95% specificity in early-stage breast cancer detection. This breakthrough enables us to distinguish cancer-associated RNA sequences from controls and discover new, unique transcripts, paving the way for a strong predictive diagnostic for early-stage breast cancer—arguably one of the most challenging cancers to diagnose via liquid biopsy. Read our full press release for more detail: https://lnkd.in/deKsv3WH If you're attending EDCC and want to learn more about our results, join our Founder and CEO, Dr. Richard Kuo and Chief Medical Officer, Dr. Richard Hockett at the poster session today at from 15:10-15:55. A huge thank you to the entire Wobble Genomics Ltd for their work in achieving these milestones. And special thanks to the team at M+F Health (Anna Hollaway, Claudia Bolouri, Kirsty Clark, Jonathan Baily & Georgia Bron) for their exceptional support during our emergence from stealth mode. There are more exciting developments ahead! 👀 #EdxConf24

We’re thrilled to announce that Wobble Genomics has officially emerged from stealth mode 🚀 To introduce ourselves, we are a pioneering healthcare and biotechnology company at the forefront of long-read RNA sequencing. Today, at the Early Detection of Cancer Conference 2024, the team will present data demonstrating that our technology can detect rare full-length RNA transcript variants not picked up by other methods. We look forward to collaborating with leading academics and researchers across the world to ultimately improve patient care. Read the full press release here: https://lnkd.in/deKsv3WH #EdxConf24

After a period of focused innovation, we can’t wait to share what we’ve been working on – stay tuned as we prepare to emerge from stealth mode 👀 We’re looking forward to presenting our findings tomorrow at Early Detection of Cancer Conference 2024 🧬 #EdxConf24